Clinical Trials · NCT06348264
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Peking University First Hospital
- Enrollment
- 37
- Start date
- Oct 2024
- Locations
- 2 sites, China
- Primary endpoint
- 3-year disease-free survival (DFS)